TrialDiabetes, obesity & metabolism2019

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.

Ronan Roussel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.